Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer

Abstract

OPN alone or in combination with bone markers is useful as diagnostic marker in the detection of bone metastases and as prognosticator in the survival prediction in PCa patients.

New Dual Monoclonal ELISA for Measuring Plasma Osteopontin as a Biomarker Associated with Survival in Prostate Cancer: Clinical Validation and Comparison of Multiple ELISAs

“…Although many studies have suggested that OPN has potential clinical utility as a biomarker in multiple tumor types in both blood and tumor tissue, few studies have provided clinical outcome data on patients. Where clinical information has been provided, OPN concentrations have been associated with patient prognosis and survival, in studies of breast (6,7 ), prostate (8,9 ), and other (10 -12 ) cancers. Recent work by Bramwell et al (7 ) showed that serial monitoring for changes in plasma OPN concentrations over time in women with metastatic breast cancer provided information useful in patient management.…”

Osteopontin but not osteonectin favors the metastatic growth of pancreatic cancer cell lines

“…[43][44][45][46][47][48][49] Parallel to upregulated expression in tumor tissues, elevated OPN plasma levels seem to be a marker for metastatic progression and poor survival in patients with cervix, breast, prostate and pancreatic cancers. 47,[50][51][52][53][54] We found a 2.2-fold and 1.6-fold increase in OPN mRNA in pancreatic cancer and chronic pancreatitis samples, respectively, compared to normal pancreatic tissues. 9 The observed upregulation of both, ON and OPN in PDAC hints to a causal involvement of the two proteins.…”

Changes in the rate of PSA progression and the level of alkaline phosphatase during high dose vitamin C treatment of patients with prostate cancer

“…According to a large multivariate analysis of patients with metastatic androgen-independent prostate cancer, elevated serum ALP levels were independently associated with shorter survival [44]. Moreover, ALP levels have been associated with the progression of skeletal metastases in patients with prostate cancer [45] and have also been shown to be significant predictors of early death [46,47]. While osteoclastic processes are seen as a potential target for prostate cancer therapy, chemotherapeutic drugs aimed at inhibition these processes offer only a few months advantage over placebo in prolonging survival time [48], and often carry side effects such as osteonecrosis of the jaw, hypocalcemia, and deterioration of renal function [49].…”